Fabry’s Disease Pipeline Analysis 2019 (H1)

Fabry’s Disease Pipeline Analysis report covers more than 15S drugs currently in different phases of development. Fabry’s disease is a rare genetic disorder caused mostly in males than females due to the deficiency of the alpha-galactosidase A (a-Gal A) enzyme which causes a build-up of a type of fat, globotriaosylceramide (Gb3, or GL-3) in the body. It is also categorized as a type of lysosomal storage disorder. The disease affects skin, eyes, gastrointestinal system, kidney, heart, brain and nervous system among other body parts.

The report provides Fabry’s Disease treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Biosidus, Sanofi, Amicus Therapeutics, Inc., Protalix and Neuraltus Pharmaceuticals, Inc.among others.

Scope:

By Company

By Phase

By Molecule Type

By Region

By Route of Administration

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Protalix
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.1.5. Recent Development
6.2. Amicus Therapeutics, Inc.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.2.5. Recent Development
6.3. Resverlogix Corp.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.3.5. Recent Development
6.4. Idorsia Pharmaceuticals Ltd
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.4.5. Recent Development
6.5. AVROBIO, Inc
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.5.5. Recent Development
6.6. Greenovation Biotech GmbH
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.6.5. Recent Development
6.7. JCR Pharmaceuticals Co., Ltd.
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.7.5. Recent Development
6.8. Pharming Group NV
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.8.5. Recent Development
6.9. Sangamo Therapeutics, Inc.
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.9.5. Recent Development
6.10. Sanofi
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.10.5. Recent Development
6.11. GREEN CROSS CORP.
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.11.5. Recent Development
6.12. BIOSIDUS
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.12.5. Recent Development
6.13. Neuraltus Pharmaceuticals, Inc.
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.13.5. Recent Development
6.14. Alexion
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.14.5. Recent Development
6.15. Sigilon Therapeutics, Inc.
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT
6.15.5. Recent Development
6.16. AMO Pharma
6.16.1. Introduction
6.16.2. Financials
6.16.3. Products and Services
6.16.4. SWOT
6.16.5. Recent Development
6.17. Oxyrane
6.17.1. Introduction
6.17.2. Financials
6.17.3. Products and Services
6.17.4. SWOT
6.17.5. Recent Development
List of Tables
List of Figures

Protalix
Amicus Therapeutics, Inc.
Resverlogix Corp.
Idorsia Pharmaceuticals Ltd
AVROBIO, Inc
Greenovation Biotech GmbH
JCR Pharmaceuticals Co., Ltd.
Pharming Group NV
Sangamo Therapeutics, Inc.
Sanofi
GREEN CROSS CORP.
BIOSIDUS
Neuraltus Pharmaceuticals, Inc.
Alexion
Sigilon Therapeutics, Inc.
AMO Pharma
Oxyrane